Castrate-Resistant Prostate Cancer Market Size, Share, Trends, Industry Analysis Report: By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy) and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Castrate-Resistant Prostate Cancer Market Size, Share, Trends, Industry Analysis Report: By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy) and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034

The castrate-resistant prostate cancer (CRPC) market size is expected to reach USD 29.79 billion by 2034, according to a new study by Polaris Market Research. The report “Castrate-Resistant Prostate Cancer Market Share, Size, Trends, Industry Analysis Report: By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy) and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The castrate-resistant prostate cancer market growth is attributed to increasing incidence rates, especially among aging populations. Prostate cancer often progresses to a more advanced, treatment-resistant stage. Thus, the demand for effective therapies has grown, leading to advancements in targeted treatments and precision oncology. Key players such as Sanofi S.A.; Johnson & Johnson; Pfizer, Inc.; Bayer AG; and Astellas Pharma, Inc. drive this market with leading products and continued innovation. The CRPC market size has expanded as major companies focus on novel therapies such as androgen receptor inhibitors, immunotherapies, and other targeted approaches. Such advancements have contributed to increased market share among companies offering comprehensive CRPC treatment options.

Do you have questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/castrate-resistant-prostate-cancer-market/request-for-sample

The castrate-resistant prostate cancer market trends indicate a shift toward personalized medicine and combination therapies that offer enhanced efficacy with fewer side effects. North America dominates the global market due to robust healthcare infrastructure, high awareness, and established medical research institutions. However, Asia Pacific is expected to witness the highest CAGR due to rising prostate cancer incidence, improved healthcare access, and regulatory support for new treatments. The castrate-resistant prostate cancer market (CRPC) market growth in these regions reflects a broader global trend of increasing investments in oncology research and treatment. Additionally, partnerships, and mergers and acquisitions are prevalent, as companies seek to expand their product pipelines and geographic reach, further fueling the castrate-resistant prostate cancer market expansion.

Castrate-Resistant Prostate Cancer Market Report Highlights

In terms of therapy, in 2024, the hormonal therapy segment accounted for the largest share of the castrate-resistant prostate cancer market due to its proven effectiveness in slowing disease progression by reducing androgen levels.

The immunotherapy segment is expected to witness the highest CAGR during the forecast period due to its ability to harness the body’s immune system to specifically target and attack prostate cancer cells, offering a promising and less invasive treatment option.

In 2024, North America dominated the castrate-resistant prostate cancer market share due to its advanced healthcare infrastructure and high prevalence of prostate cancer.

The Asia Pacific market is expected to witness significant growth during the forecast period due to the growing awareness of advanced treatment options and supportive government initiatives in cancer care.

A few global key market players are Sanofi S.A.; Johnson and Johnson; Pfizer, Inc.; Bayer AG; Abbott Laboratories; GlaxoSmithKline PLC; Northwest Biotherapeutics, Inc.; Active Biotech AB; Astellas Pharma, Inc; and Dendreon Corporation.

Polaris Market Research has segmented the castrate-resistant prostate cancer market report on the basis of therapy, and region:

By Therapy Outlook (Revenue, USD Billion; 2020–2034)

Chemotherapy

Hormonal Therapy

Immunotherapy

Radiotherapy

By Regional Outlook (Revenue, USD Billion; 2020–2034)

North America

• US
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Australia
• Rest of Asia Pacific

Latin America

• Argentina
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of Middle East & Africa